Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Dstl has a requirement to access commercially available services related to the production and purification of recombinant antibodies, associated molecular biology services, as well as infrequently accessed, or emerging technologies in this general area.
All aspects of the requirement are described as optional work packages, with an estimated volume of work provided in good faith, but without commitment.
No supplier information available.